Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. 2018

Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti-human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti-HER2 drug presently available for gastric cancer. In this study, we propose novel treatment options for patients with HER2-positive gastric cancer. First, we determined the molecular profiles of 12 gastric cancer cell lines, and examined the antitumor effect of the pan-HER inhibitors afatinib and neratinib in those cell lines. Additionally, we analyzed HER2 alteration in 123 primary gastric cancers resected from Japanese patients to clarify possible candidates with the potential to respond to these drugs. In the drug sensitivity analysis, both afatinib and neratinib produced an antitumor effect in most of the HER2-amplified cell lines. However, some cells were not sensitive to the drugs. When the molecular profiles of the cells were compared based on the drug sensitivities, we found that cancer cells with lower mRNA expression levels of IGFBP7, a tumor suppressor gene that inhibits the activation of insulin-like growth factor-1 receptor (IGF-1R), were less sensitive to pan-HER inhibitors. A combination therapy consisting of pan-HER inhibitors and an IGF-1R inhibitor, picropodophyllin, showed a notable synergistic effect. Among 123 clinical samples, we found 19 cases of HER2 amplification and three cases of oncogenic mutations. In conclusion, afatinib and neratinib are promising therapeutic options for the treatment of HER2-amplified gastric cancer. In addition to HER2 amplification, IGFBP7 might be a biomarker of sensitivity to these drugs, and IGF-1R-targeting therapy can overcome drug insensitiveness in HER2-amplified gastric cancer.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017526 Receptor, IGF Type 1 A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain. IGF Type 1 Receptor,IGF-I Receptor,Receptor, IGF-I,Receptor, Insulin-Like Growth Factor I,Receptor, Insulin-Like Growth Factor Type 1,IGF-1 Receptor,Insulin-Like-Growth Factor I Receptor,Receptor, IGF Type 1 alpha Subunit,Receptor, IGF Type 1 beta Subunit,Receptors, IGF-1,Receptors, Insulin-Like-Growth Factor I,IGF 1 Receptor,IGF I Receptor,IGF-1 Receptors,Insulin Like Growth Factor I Receptor,Receptor, IGF I,Receptor, IGF-1,Receptors, IGF 1
D044466 Asian People Persons having origins in any of the Asian racial groups of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. Note that OMB category ASIAN is available for United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. Asian Continental Ancestry Group,Asian Person,Asiatic Race,Mongoloid Race,Asian Peoples,Asian Persons,Asiatic Races,Mongoloid Races,People, Asian,Person, Asian,Race, Asiatic,Race, Mongoloid

Related Publications

Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
September 2018, Clinical lung cancer,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
March 2012, Anti-cancer drugs,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
January 2023, Oncology research and treatment,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
January 2023, Frontiers in pharmacology,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
November 2015, BMC cancer,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
February 2015, Molecular oncology,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
September 2005, Cancer letters,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
May 2024, MedComm,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
July 2012, BMC medicine,
Takahiro Yoshioka, and Kazuhiko Shien, and Kei Namba, and Hidejiro Torigoe, and Hiroki Sato, and Shuta Tomida, and Hiromasa Yamamoto, and Hiroaki Asano, and Junichi Soh, and Kazunori Tsukuda, and Takeshi Nagasaka, and Toshiyoshi Fujiwara, and Shinichi Toyooka
September 2016, Clinical lung cancer,
Copied contents to your clipboard!